#SLE pts have equal rates of post op CV events compared to TypeII DM pts and ⬆️ compared to matched controls. Esp driven by comorbidities. Should we add ASA post op in SLE pts with CV risks? #ACR21 #abst0128 @RheumNow https://t.co/COdbDxFgBQ

Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic changes in FMF+axSpA suggested worse disease. Rate of amyloidosis and hip involvement were higher in FMF+axSpA pts. Abs 0378 #ACR21 #RheumNow @RheumNow https://t.co/lUmn3A90Ob https://t.co/n3kj8GcV1i

• Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloar…

KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉phase 3 DBRPCT 24 weeks 👉150 mg week 0,4, 16 weeks 👉improved ACR20,ACR50,ACR70 👉improved PASI90 👉improved HAQ-DI 👉no increased safety signals #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi

Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database - Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq

#ACR21 Abst#0454 Lupus nephritis mortality from 1999-2019 ⭐️-27% age-standardized mortality rate in LN death, though increased trend in last 5 yrs! ▶️ Afr-American 38% of deaths, though 12% of population (RR ~4.5), ⬆️mortality with urbanization https://t.co/fjeGXtItvD @RheumNow https://t.co/cE3t6lq8zi

• https://bit.ly/3CNsuEm

Promising results of Risankizumab for #psoriaticarthritis 🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo 🔸Well tolerated and showed no safety signals @RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g

#ACR21 @RheumNow Abst#0450 Hwang et al. from the PSOAS cohort analyzed 1618 radiographs between 2002-2017 ⭐️Higher spinal disease: Male gender; longer disease duration; smoking ⭐️🔼Disease progression 🔼CRP levels ⭐️🔽Disease progression with time-varying TNFI use https://t.co/XsKp28HOxz

Pre clinical RA: don't miss the feet 🦶🏼! Among 577 patients with clinically suspect arthralgia undergoing MRI: -23% intermetatarsal bursitis > ACPA + 56% vs. 19% -higher risk or RA HR 3.3. Would we find the same results w/ US? #OP0468 @RheumNow #ACR2021 https://t.co/VkzUu93qGq https://t.co/GGw7UgdPVR

• During Development of Rheumatoid Arthritis, Intermetatarsal Bursitis May Occur …

Accdg to this study by Dr. B VanDijk et al, intermetatarsal bursitis (IMB) was seen in 23% of clin suspect arthralgia(CSA) pts; predicted clinical arthritis in ACPA+; ⬆ frequent w/ synovitis & tenosynovitis Addtl tool for early RA dx? @RheumNow #ACR21 abs0468 #ACRBest https://t.co/bcUuy8bHLJ

AxSpA pts share a gut microbiome signature with Crohn's disease and anterior uveitis pts ⬇️Blautia ⬆️Veillonella and Lactobacillus ⭐️SpA pts uniquely enriched in Collinsella Abs#0062 #ACR21 @RheumNow #ACRBest https://t.co/sdlHxNbhr8 https://t.co/r8eG9c9vwa

• Axial Spondyloarthritis and Its Related Immune-Mediated Diseases Share a Gut Mi…

Early axSpA DESIR: higher dz activity & worse function independently assoc'd w/ ^ hazard of Work Disability vs SES. Dz severity strong predictor of adverse work outcome despite advanced therapeutic strategies in axSpA. Abs 0381 #ACR21 #RheumNow @RheumNow https://t.co/Lc3yUgXvw6

• How Do Clinical and Socioeconomic Factors Impact on Work Disability in Early Ax…

#ACR21 Abst#0455 ARIAA Study: Abatacept for subclinical arthritis ⭐️ ACPA + arthralgia + MRI inflammation 🔥 ⭐️ ⬇️ MRI inflam (primary) and ⬇️ progression to arthritis (secondary) ▶️ Many patients likely early RA, would still rec starting MTX 1st https://t.co/4aREvqlpUI @Rheumnow https://t.co/vqRgsd75Il

• https://bit.ly/3ES6vg4

#ACR21 Abst#0293: Lung involvement in 67 sero+ RA pts assoc w/: ⭐︎ SSc-specific ab ➡️ RP155, Th/To, fibrillarin, NOR90 in ILD group ➡️ Ku, Pm/Scl100, CENP-A/B in non-ILD group ⭐︎ older age, ⚦ sex, heavy 🚬 ⭐︎ ↑ WBC, CRP, RF #ACRBest @Rheumnow https://t.co/Yo4jRKqvfV https://t.co/l5gbKoZBkm

• Increased Prevalence of Scleroderma Specific Autoantibodies in Seropositive Rhe…

Yikes! Higher rates of lupus nephritis deaths in last 5 years 👉8900 lupus nephritis deaths in USA studied race/ethnicity and urbanization assc w/ LN mortality 👉highest in blacks and large central metro regions #ACR21 #Plenary Abstr# 0454 @rheumnow https://t.co/bxQvID8jht

Nice graphic presentation of the results! Dr. Katie Liao and her group present the characteristics and disease manifestations of Ro+ #SLE patients from the Australian #lupus registry and biobank @RheumNow #ACR21 abs0323 https://t.co/Yl5sZgiTw1